Literature DB >> 32631771

COVID-19 associated Kawasaki-like multisystem inflammatory disease in an adult.

Sabrina Sokolovsky1, Parita Soni2, Taryn Hoffman1, Philip Kahn3, Joshua Scheers-Masters4.   

Abstract

Recent reports have described a secondary Multisystem Inflammatory Syndrome in Children (MIS-C) after a prior COVID-19 infection that often has features of Kawasaki disease (KD). Here, we report the case of a 36-year-old woman who presented to the emergency department hypotensive and tachycardic after 1 week of fevers, abdominal pain, vomiting and diarrhea, and was found to have the classic phenotype of complete Kawasaki's Disease including nonexudative conjunctivitis, cracked lips, edema of the hands and feet, palmar erythema, a diffuse maculopapular rash, and cervical lymphadenopathy. Initial laboratory studies were significant for hyponatremia, elevated liver function tests including direct hyperbilirubinemia, and leukocytosis with neutrophilia. Imaging revealed mild gallbladder wall edema, a small area of colitis, and small pleural effusion. She was treated for Kawasaki Disease Shock Syndrome (KDSS) with pulse dose solumedrol, IVIG, and aspirin with near resolution of symptoms and normalization of vital signs within 1 day and subsequent improvement in her laboratory abnormalities. She was later found to be COVID-19 IgG positive, suggesting past exposure. This case represents an early report of a KD-like illness in an adult with serologic evidence of a previous COVID-19 infection, similar to MIS-C. It suggests that the virulent strain of SARS-CoV-2 appears to cause a post-infectious inflammatory syndrome similar to KD in adults, as well as children. Our understanding of the myriad of COVID-19 symptoms and sequelae is rapidly evolving. We recommend physicians remain vigilant for inflammatory syndromes that mimic KD/KDSS which may warrant prompt treatment with IVIG and steroids.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  COVID-19; Kawasaki Disease Shock Syndrome; Kawasaki disease; Multisystem Inflammatory Syndrome

Year:  2020        PMID: 32631771      PMCID: PMC7315983          DOI: 10.1016/j.ajem.2020.06.053

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


Introduction

Recent reports have described a secondary Multisystem Inflammatory Syndrome in Children (MIS-C) after a prior COVID-19 infection, who have presented with features of Kawasaki disease (KD) [1,2]. Recently, there are media reports of young adults in their late teens and early twenties with the same syndrome [3]. The following case describes the clinical features, treatment, and response of an adult who presented with a KD-like inflammatory disorder, similar to past reports of MIS-C, with evidence of a prior COVID-19 infection.

Case description

A 36-year-old previously healthy Hispanic female presented to the hospital with 1 week of subjective fevers, abdominal pain, vomiting, and diarrhea with 2 days of a diffuse rash and arthralgias. The patient presented to the Emergency Department febrile, tachycardic, tachypneic, hypotensive and with the classic phenotype of complete Kawasaki's Disease [4]: Bilateral nonexudative conjunctivitis (Fig. 1A); mucositis with cracked lips (Fig. 1B); edema of the bilateral hands and feet (Fig. 1C, 1D); palmar erythema (Fig. 1D); a diffuse maculopapular rash (Fig. 1E); and cervical lymphadenopathy. The constellation of findings was suspicious for Kawasaki Disease Shock Syndrome (KDSS) [5].
Fig. 1

Features of Kawasaki Disease – nonexudative conjunctivitis with heliotrope rash (1A), mucositis with cracked lips (1B), extremity edema (1C, 1D), palmar erythema (1D), diffuse maculopapular rash (1E).

Features of Kawasaki Disease – nonexudative conjunctivitis with heliotrope rash (1A), mucositis with cracked lips (1B), extremity edema (1C, 1D), palmar erythema (1D), diffuse maculopapular rash (1E). Laboratory results included leukocytosis with WBC of 25.3 K/UL (4.9–10.8), absolute neutrophilia of 19.5 K/UL (1.4–6.5) without significant lymphopenia (absolute lymphocytes 1.1 K/UL [1.2–3.4]), mild normocytic anemia (Hgb 10.8 g/dL [12-16]), and normal platelets. The patient had hyponatremia of 115 mmol/L (133–146), and abnormal LFTs with AST 81 IU/L (10−33), ALT 116 IU/L (6–47), ALP 311 IU/L (36–112), direct hyperbilirubinemia (total bilirubin 3.9 mg/dL [0.2–1.4], direct bilirubin 2.4 mg/dL [0.0–0.2]). Serum albumin was decreased at 2.5 g/dL (3.5–5.2) and INR increased to 2. ESR was 30 mm/h (0−20), CRP: 30 mg/dL (0.0–0.9), and d-dimer: 652 ng/mL (<318). ANA was 1:160 (<1:80), SSA was 2.8 (<0.9), with C3 of 59 mg/dL (81–157) and C4 of 12 mg/dL (13–39); however anti-dsDNA, anti-smith, anti-RNP, SSB, RF, CCP, ANCA, ASO, and anti-Jo-1 antibodies were negative. HIV and hepatitis panels were negative. A bedside right upper quadrant ultrasound revealed mild gallbladder wall edema. CT angiogram of the chest revealed normal lung parenchyma and a trace right pleural effusion. CT abdomen/pelvis illustrated mild circumferential gallbladder wall thickening and a small area of colitis; all of which have been seen in KD and previously reported in MIS-C [1]. Echocardiogram after treatment with IVIG revealed an EF of 65% with moderate tricuspid valve regurgitation. Subsequent CTA coronaries was normal except for a trace pericardial effusion. COVID-19 testing revealed positive PCR, as well as a positive IgG with negative IgM antibodies. Treatment was initiated with fluid resuscitation for shock, a single dose of aspirin 650 mg, IVIG 2 g/kg, and methylprednisolone 2 mg/kg for 5 days followed by a prednisone taper. The patient experienced a near resolution of symptoms and normalization of vital signs within 1 day. Inflammatory markers and hyperbilirubinemia improved rapidly over 6 days. AST, ALT, and ALP initially rose but trended down during this time. The patient was discharged home on prednisone.

Discussion

This case represents an early report of a KD-like illness in an adult with serologic evidence of a previous COVID-19 infection, similar to MIS-C. KD is a rare illness in pediatrics and even more rare in adults. However, the virulent strain of SARS-CoV-2 appears to cause a post-infectious inflammatory syndrome similar to KD in both the pediatric and adult populations. While our patient met criteria for KD, there are inconsistent features such as a heliotrope rash with prominent plate-like scaling (Fig. 1A) and hypocomplementemia. Repeat ANA and SSA antibodies will be needed to determine persistence. These low titers do not appear consistent with her presentation and may be clinically insignificant.

Conclusion

Our understanding of the myriad of COVID-19 symptoms and sequelae is rapidly evolving. We recommend physicians remain vigilant for secondary inflammatory syndromes that mimic KD/KDSS which may warrant prompt treatment with IVIG and steroids.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
  27 in total

1.  MicroRNAs as the Potential Regulators of SARS-CoV-2 Infection and Modifiers of the COVID-19 Clinical Features.

Authors:  A N Kucher; Iu A Koroleva; A A Zarubin; M S Nazarenko
Journal:  Mol Biol       Date:  2022-02-12       Impact factor: 1.540

Review 2.  Deciphering SARS-CoV-2 Virologic and Immunologic Features.

Authors:  Grégorie Lebeau; Damien Vagner; Étienne Frumence; Franck Ah-Pine; Xavier Guillot; Estelle Nobécourt; Loïc Raffray; Philippe Gasque
Journal:  Int J Mol Sci       Date:  2020-08-18       Impact factor: 5.923

3.  [COVID-19 associated Kawasaki-like multisystem inflammatory syndrome in an adult].

Authors:  Y Elouardi; H Rebahi; Y Zarrouki; A Ziadi; S Younous; M A Samkaoui
Journal:  Rev Esp Anestesiol Reanim       Date:  2020-12-26

Review 4.  Multisystem inflammatory syndrome in children related to COVID-19: a systematic review.

Authors:  Levi Hoste; Ruben Van Paemel; Filomeen Haerynck
Journal:  Eur J Pediatr       Date:  2021-02-18       Impact factor: 3.183

5.  Pathogenesis, Symptomatology, and Transmission of SARS-CoV-2 through analysis of Viral Genomics and Structure.

Authors:  Halie M Rando; Adam L MacLean; Alexandra J Lee; Sandipan Ray; Vikas Bansal; Ashwin N Skelly; Elizabeth Sell; John J Dziak; Lamonica Shinholster; Lucy D'Agostino McGowan; Marouen Ben Guebila; Nils Wellhausen; Sergey Knyazev; Simina M Boca; Stephen Capone; Yanjun Qi; YoSon Park; Yuchen Sun; David Mai; Christian Brueffer; James Brian Byrd; Jinhui Wang; Ronan Lordan; Ryan Velazquez; Gregory L Szeto; John P Barton; Rishi Raj Goel; Serghei Mangul; Tiago Lubiana; Anthony Gitter; Casey S Greene
Journal:  ArXiv       Date:  2021-02-01

6.  Two adult cases of multisystem inflammatory syndrome associated with SARS-CoV-2.

Authors:  Karolina Mieczkowska; Tian Hao Zhu; Lauren Hoffman; Rachel C Blasiak; Kenneth J Shulman; Mathew Birnbaum; David H Ciocon; Rithu Srikantha; Beth N McLellan
Journal:  JAAD Case Rep       Date:  2021-02-23

Review 7.  Rheumatological complications of Covid 19.

Authors:  Hannah Zacharias; Shirish Dubey; Gouri Koduri; David D'Cruz
Journal:  Autoimmun Rev       Date:  2021-07-05       Impact factor: 9.754

8.  Multisystem Inflammatory Syndrome in an Adult (MIS-A) Successfully Treated with Anakinra and Glucocorticoids.

Authors:  Paolo Cattaneo; Alessandro Volpe; Chiara Simona Cardellino; Niccolò Riccardi; Giulia Bertoli; Tamara Ursini; Arjola Ustalli; Giovanni Lodi; Ivan Daroui; Andrea Angheben
Journal:  Microorganisms       Date:  2021-06-28

Review 9.  Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management.

Authors:  Jayakanthan Kabeerdoss; Rakesh Kumar Pilania; Reena Karkhele; T Sathish Kumar; Debashish Danda; Surjit Singh
Journal:  Rheumatol Int       Date:  2020-11-21       Impact factor: 2.631

10.  Case Report: Adult Post-COVID-19 Multisystem Inflammatory Syndrome and Thrombotic Microangiopathy.

Authors:  Idris Boudhabhay; Marion Rabant; Lubka T Roumenina; Louis-Marie Coupry; Victoria Poillerat; Armance Marchal; Véronique Frémeaux-Bacchi; Khalil El Karoui; Mehran Monchi; Franck Pourcine
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.